ACELYRIN, INC. to host virtual investor event to share Phase 2 data for lonigutamab in treating TED.
From GlobeNewswire: 2025-01-02 20:00:00
ACELRYN, INC. will host a virtual investor event to provide updated Phase 2 data for subcutaneous lonigutamab in treating Thyroid Eye Disease (TED). The event will feature external clinician perspectives and will disclose the design for the Phase 3 LONGITUDE program. ACELYRIN CEO and other key executives will be joined by Drs. Andrea Kossler and Prem Subramanian to discuss the continuing unmet needs in TED. Lonigutamab is a humanized IgG1 monoclonal antibody targeting the anti-insulin-like growth factor 1 receptor, offering potential for a best-in-class efficacy and safety profile. TED is a vision-threatening autoimmune disease affecting over 100,000 people in the U.S.
Dr. Andrea Kossler is an Associate Professor of Ophthalmology at Stanford University specializing in aesthetic oculofacial surgery and thyroid eye disease. Dr. Prem Subramanian is the Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology at the University of Colorado focusing on thyroid ophthalmopathy and vision problems in patients with increased intracranial pressure. ACELYRIN is focused on accelerating the development and commercialization of transformative medicines, with lonigutamab being a lead program for the treatment of thyroid eye disease.
The company’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R. ACELYRIN aims to provide life-changing new treatment options for patients by identifying and accelerating the development of transformative medicines. Forward-looking statements in the press release include expectations regarding funding milestones, development activities, and the therapeutic potential of the company’s product candidates. Risk factors include the successful completion of development activities, maintaining intellectual property protection, and market volatility. ACELYRIN Contacts: Tyler Marciniak, Vice President of Investor Relations and Corporate Affairs.
Read more at GlobeNewswire: ACELYRIN, INC. to Host Virtual Investor Event to Share new